That was my takeaway as well--that the safety of the viricide was demonstrated. And now it is a matter of "tweaking" the viricide to increase the efficacy against the Ebola virus. Since safety and efficacy are of paramount importance and a company cannot proceed without demonstrating both, this PR, to me, provides a great deal of promise and hope for NNVC investors. Unfortunately, progress is measured in glacial speed which is not always to an investor's advantage. Tying up our investment dollars requires a lot of discipline and faith. Very few shareholders in biological startup companies are truly rewarded. Currently, the few who have managed to be aggressively nimble with their buys and sells are the ones who are "making money" with NNVC. The rest of us anticipate the day when our patience will be rewarded. I still have faith, although I am wishing I had more courage to act on the buy/sell side of things. Good luck to all NNVC shareholders as we await the new paradigm.
Lee
News 
Market Data 
Discover 
